Flinn.ai, a Vienna-based leader in automating regulatory and quality compliance for medtech companies, has secured €10 million in investment, led by Cherry Ventures. This funding will accelerate the company’s product development and market expansion, particularly for its AI-driven compliance modules.
The company’s SaaS solutions streamline compliance processes, making them ten times more efficient by incorporating AI for data processing, evaluation, and reporting. With growing complexities in the medtech industry—especially following the introduction of the EU Medical Device Regulation (MDR)—Flinn.ai offers a lifeline to companies facing increased compliance costs.
Bastian Krapinger-Rüther, co-founder and CEO of Flinn.ai, commented: “Our AI solutions have the potential to significantly enhance the quality of medical devices while simplifying regulatory processes. This investment brings us closer to making high-quality healthcare accessible to everyone.”
The investment round also saw participation from Speedinvest, SquareOne, and well-known business angels like Matthias Weber and Michael Reitermann.
With the medtech industry becoming more regulated, Filip Dames, Partner at Cherry Ventures, emphasized Flinn.ai’s strategic advantage: “As compliance requirements grow more complex, Flinn.ai’s solutions stand out by offering much-needed automation for a traditionally underserved market.”
Medtech companies like Erbe Elektromedizin GmbH have already seen the impact, with CTO Helmut Scherer praising Flinn.ai’s ability to streamline safety database monitoring, reduce personnel costs, and increase employee satisfaction by automating repetitive tasks.